<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762320</url>
  </required_header>
  <id_info>
    <org_study_id>08-017</org_study_id>
    <nct_id>NCT00762320</nct_id>
  </id_info>
  <brief_title>Comparison of Liquid Kaletra and Low Dose Kaletra Tablets</brief_title>
  <official_title>Comparison of Liquid Kaletra and Low Dose Kaletra Tablets in HIV-Positive Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Phoenix Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kaletra (a combination drug with lopinavir and ritonavir) is one of a few effective
      medications that are approved and available for young children who are HIV+. The liquid form
      is reported to have a very nasty taste and presents difficulties for the children who must
      take the medication twice a day and for their parents who must enforce the medication
      regimen. The children are often well into their teens before they weigh enough to be able to
      take the adult dose tablet (200mg/50mg). A new smaller dose tablet (100mg/25mg) is now
      available. However, it is not known if the liquid and tablet act the same in children. The
      purpose of this study is to switch children from the baseline treatment with the liquid to
      the study intervention treatment with 100mg/25mg tablet form of Kaletra. The study will
      compare children pre-switch and post-switch in terms of how well their HIV is controlled .
      Comparisons of parent and child satisfaction will also be made. Eight to 10 HIV+ children
      currently well managed with a medications including liquid Kaletra will be invited to switch
      from the liquid to the low dose Kaletra tablet. The parent and/or child will complete a
      satisfaction survey for the liquid Kaletra and lab values will be taken from the chart. At
      the time of the switch and 1, 3 and 6 months post switch blood tests will be drawn and the
      parent and/or child will complete the satisfaction survey. In addition, at the switch and 1
      month post switch, a day will be spent in clinic with 5 blood draws to see how much of the
      drug is in the blood stream at different times after the medicine is taken.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute CD4 and CD4 %</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks, 26 weeks</time_frame>
    <description>Number of participants who had no clinically significant deterioration in absolute CD4 and % CD4 count for the duration of the study. Absolute CD4 and Percent CD4 counts were determined by single or dual platform analysis performed on blood samples by Phoenix Children's Hospital Laboratory, Sonora Quest Laboratory or Labcorp Laboratory. Clinically significant change was determine to be a deterioration in both Absolute CD4 to less than 500 and %CD4 to less than 25%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lopinavir (Lpv) and Ritonavir (Rtv) Maximumu Plasma Concentration (CMax) Liquid</measure>
    <time_frame>Baseline</time_frame>
    <description>Cmax values at baseline (participants are taking liquid Kaletra as part of baseline treatment). Time points for data collection: 0, 2hrs post dose, 4 hrs post dose, 8 hrs post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lopinavir and Ritonavir Area Under the Curve (AUC) Liquid Kaletra</measure>
    <time_frame>Baseline</time_frame>
    <description>Area under the curve values for lopinavir at baseline when participants are taking liquid Kaletra as part of their baseline treatment. Time points for data collection: 0, 2 hrs post, 4 hrs post, 6 hrs post, 8 hrs post.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lopinavir AUC Ratio of Baseline:Week 4</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>Ratio of AUC at baseline (liquid)to week 4 (reduced dose tablet). AUC data were collected at 0, 2, 4, 6, and 8 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load (VL)</measure>
    <time_frame>Baseline, Week 4, Week 12 and Week 24</time_frame>
    <description>Number of participants who maintained their Viral load undetectable (&lt; 20 copies/ml) for the duration of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lopinavir (Lpv) and Ritonavir (Rtv) Cmax at 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Lpv and rtv Cmax at 4 weeks when participants are receiving study intervention, low dose Kaletra. Time points for data collection: 0, 2hrs, 4hrs, 6hrs, 8hrs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lopinavir and Ritonavir AUC on Low Dose Tablet</measure>
    <time_frame>4 weeks</time_frame>
    <description>Lopinavir and Ritonavir AUC at 4 weeks when participants are receiving the study intervention, low dose tablet formulation of Kaletra. Data collection points for AUC were 0, 2, 4, 6, and 8 hours post dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>Baseline, 1 month</time_frame>
    <description>Patient Satisfaction Survey. Eight item Likert scale of patient satisfaction with their HIV treatment regimen for patients 7 years of age and older. Items scores are summed to compute a total score. Total scores are reported with a minimum of 0 and a maximum of 32, with higher scores indicating higher satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms Across All Patients</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months</time_frame>
    <description>Cumulative tally of symptoms for each patients across all visits. Targetted symptoms were asked for at each visit and patients and parents were encouraged to report additional symptoms that were experienced. Each patient got a score for the total number of symptoms at each visit. Scores were totalled, but it the same symptoms occurred continuously it was counted as 1 symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent Satisfaction</measure>
    <time_frame>Baseline, 4 week, 12 weeks and 24 weeks</time_frame>
    <description>Parent Satisfaction Survey. Eight item Likert scale of parent/guardian satisfaction with the child's HIV treatment regimen. Item scores are summed to compute a total score. Total scores are reported with a minimum of 0 and a maximum of 32, with higher scores indicating higher satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Low dose Kaletra tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Kaletra tablets</intervention_name>
    <description>Lopinavir/Ritonavir tablets 100mg/25mg</description>
    <arm_group_label>Low dose Kaletra tablets</arm_group_label>
    <other_name>lopinavir/ritonavir 100mg/25mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV+ children aged 3-18.

          -  Baseline treatment includes liquid Kaletra

          -  currently on a stable (on same regimen &gt; 3 months, Viral Load&lt; 5,000), Highly Active
             Antiretroviral Therapy (HAART) regimen

          -  able to take pills or willing to undergo pill training prior to enrollment

          -  weight must be greater than or equal to 15kg

        Exclusion Criteria:

          -  Unable to swallow pills

          -  Concomitant treatment with Rifampin or St. John's Wort which have been shown to
             decrease plasma concentrations of lopinavir.

          -  Concurrent use of drugs primarily metabolized by CYP3A, which metabolizes ritonavir:
             Astemizole, Cisapride, Dihydroergotamine, Ergonovine, Ergotamine, Flecainide,
             Lovastatin, Methylergonovine, Midazolam, Pimozide, Propafenone, Simvastatin,
             terfenadine, Triazolam

          -  Baseline treatment does NOT include Kaletra
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Piatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>November 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2014</results_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Phoenix Children's Hospital</investigator_affiliation>
    <investigator_full_name>Janice Piatt</investigator_full_name>
    <investigator_title>Medical Director, Bill Holt Clinic</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Kaletra</keyword>
  <keyword>treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients weighing 15kg and able to swallow pills, currently taking liquid lpv/rtv were recruited from an outpatient pediatric HIV clinic from 4/1/2009 through 1/12/11</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Kaletra</title>
          <description>Patients will serve as their own controls as they are switched from liquid Kaletra to Low Dose Tablet Kaletra
Low dose Kaletra tablets : Lopinavir/Ritonavir tablets 100mg/25mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Kaletra</title>
          <description>Patients will serve as their own controls as they are switched from liquid Kaletra to Low Dose Tablet Kaletra
Low dose Kaletra tablets : Lopinavir/Ritonavir tablets 100mg/25mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.18" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute CD4 and CD4 %</title>
        <description>Number of participants who had no clinically significant deterioration in absolute CD4 and % CD4 count for the duration of the study. Absolute CD4 and Percent CD4 counts were determined by single or dual platform analysis performed on blood samples by Phoenix Children's Hospital Laboratory, Sonora Quest Laboratory or Labcorp Laboratory. Clinically significant change was determine to be a deterioration in both Absolute CD4 to less than 500 and %CD4 to less than 25%.</description>
        <time_frame>Baseline, 4 weeks, 12 weeks, 26 weeks</time_frame>
        <population>All participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra</title>
            <description>Patients receiving Low Dose Kaletra Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute CD4 and CD4 %</title>
          <description>Number of participants who had no clinically significant deterioration in absolute CD4 and % CD4 count for the duration of the study. Absolute CD4 and Percent CD4 counts were determined by single or dual platform analysis performed on blood samples by Phoenix Children's Hospital Laboratory, Sonora Quest Laboratory or Labcorp Laboratory. Clinically significant change was determine to be a deterioration in both Absolute CD4 to less than 500 and %CD4 to less than 25%.</description>
          <population>All participants were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lopinavir (Lpv) and Ritonavir (Rtv) Maximumu Plasma Concentration (CMax) Liquid</title>
        <description>Cmax values at baseline (participants are taking liquid Kaletra as part of baseline treatment). Time points for data collection: 0, 2hrs post dose, 4 hrs post dose, 8 hrs post dose.</description>
        <time_frame>Baseline</time_frame>
        <population>All participants were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra</title>
            <description>Patients receiving Low Dose Kaletra Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Lopinavir (Lpv) and Ritonavir (Rtv) Maximumu Plasma Concentration (CMax) Liquid</title>
          <description>Cmax values at baseline (participants are taking liquid Kaletra as part of baseline treatment). Time points for data collection: 0, 2hrs post dose, 4 hrs post dose, 8 hrs post dose.</description>
          <population>All participants were analyzed</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax Lpv</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9742" spread="2533.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Rtv</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="637.0" spread="357.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lopinavir and Ritonavir Area Under the Curve (AUC) Liquid Kaletra</title>
        <description>Area under the curve values for lopinavir at baseline when participants are taking liquid Kaletra as part of their baseline treatment. Time points for data collection: 0, 2 hrs post, 4 hrs post, 6 hrs post, 8 hrs post.</description>
        <time_frame>Baseline</time_frame>
        <population>All participants were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra</title>
            <description>Patients receiving Low Dose Kaletra Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Lopinavir and Ritonavir Area Under the Curve (AUC) Liquid Kaletra</title>
          <description>Area under the curve values for lopinavir at baseline when participants are taking liquid Kaletra as part of their baseline treatment. Time points for data collection: 0, 2 hrs post, 4 hrs post, 6 hrs post, 8 hrs post.</description>
          <population>All participants were analyzed</population>
          <units>hr*ng/ml</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lpv AUC at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90651" spread="30346.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rtv AUC at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3701.2" spread="2088.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lopinavir AUC Ratio of Baseline:Week 4</title>
        <description>Ratio of AUC at baseline (liquid)to week 4 (reduced dose tablet). AUC data were collected at 0, 2, 4, 6, and 8 hours post dose.</description>
        <time_frame>Baseline, week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra</title>
            <description>Patients receiving Low Dose Kaletra Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Lopinavir AUC Ratio of Baseline:Week 4</title>
          <description>Ratio of AUC at baseline (liquid)to week 4 (reduced dose tablet). AUC data were collected at 0, 2, 4, 6, and 8 hours post dose.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient Satisfaction Survey. Eight item Likert scale of patient satisfaction with their HIV treatment regimen for patients 7 years of age and older. Items scores are summed to compute a total score. Total scores are reported with a minimum of 0 and a maximum of 32, with higher scores indicating higher satisfaction.</description>
        <time_frame>Baseline, 1 month</time_frame>
        <population>Patients had to be able to read and write to complete the patient satisfaction questionnaire, so an arbitrary age of 7 was selected and patients under the age of 7 did not complete the patient satisfaction questionnaire. All 5 of the patients over the age of 5 completed the questionnaire and were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra Baseline Visit</title>
            <description>Patient satisfaction score at baseline visit</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Kaletra Week 4 Visit</title>
            <description>Patient Satisfaction Score at Week 4 visit</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient Satisfaction Survey. Eight item Likert scale of patient satisfaction with their HIV treatment regimen for patients 7 years of age and older. Items scores are summed to compute a total score. Total scores are reported with a minimum of 0 and a maximum of 32, with higher scores indicating higher satisfaction.</description>
          <population>Patients had to be able to read and write to complete the patient satisfaction questionnaire, so an arbitrary age of 7 was selected and patients under the age of 7 did not complete the patient satisfaction questionnaire. All 5 of the patients over the age of 5 completed the questionnaire and were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="7.76"/>
                    <measurement group_id="O2" value="21.8" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=.004</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=4</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms Across All Patients</title>
        <description>Cumulative tally of symptoms for each patients across all visits. Targetted symptoms were asked for at each visit and patients and parents were encouraged to report additional symptoms that were experienced. Each patient got a score for the total number of symptoms at each visit. Scores were totalled, but it the same symptoms occurred continuously it was counted as 1 symptom.</description>
        <time_frame>Baseline, 1 month, 3 months, 6 months</time_frame>
        <population>All participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra</title>
            <description>Patients receiving Low Dose Kaletra</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms Across All Patients</title>
          <description>Cumulative tally of symptoms for each patients across all visits. Targetted symptoms were asked for at each visit and patients and parents were encouraged to report additional symptoms that were experienced. Each patient got a score for the total number of symptoms at each visit. Scores were totalled, but it the same symptoms occurred continuously it was counted as 1 symptom.</description>
          <population>All participants analyzed</population>
          <units>numer of symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms for all subjects at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.20" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms for all subjects at 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.80" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms for all subjects at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.40" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms for all subjects at 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.60" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load (VL)</title>
        <description>Number of participants who maintained their Viral load undetectable (&lt; 20 copies/ml) for the duration of the study</description>
        <time_frame>Baseline, Week 4, Week 12 and Week 24</time_frame>
        <population>All subjects in study were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra</title>
            <description>Patients receiving Low Dose Kaletra Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load (VL)</title>
          <description>Number of participants who maintained their Viral load undetectable (&lt; 20 copies/ml) for the duration of the study</description>
          <population>All subjects in study were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lopinavir (Lpv) and Ritonavir (Rtv) Cmax at 4 Weeks</title>
        <description>Lpv and rtv Cmax at 4 weeks when participants are receiving study intervention, low dose Kaletra. Time points for data collection: 0, 2hrs, 4hrs, 6hrs, 8hrs</description>
        <time_frame>4 weeks</time_frame>
        <population>All participants were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra</title>
            <description>Patients receiving Low Dose Kaletra Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Lopinavir (Lpv) and Ritonavir (Rtv) Cmax at 4 Weeks</title>
          <description>Lpv and rtv Cmax at 4 weeks when participants are receiving study intervention, low dose Kaletra. Time points for data collection: 0, 2hrs, 4hrs, 6hrs, 8hrs</description>
          <population>All participants were analyzed</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lpv Cmax at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11143" spread="2839.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rtv Cmax at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="912.1" spread="588.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lopinavir and Ritonavir AUC on Low Dose Tablet</title>
        <description>Lopinavir and Ritonavir AUC at 4 weeks when participants are receiving the study intervention, low dose tablet formulation of Kaletra. Data collection points for AUC were 0, 2, 4, 6, and 8 hours post dose.</description>
        <time_frame>4 weeks</time_frame>
        <population>All participants were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra</title>
            <description>Patients receiving Low Dose Kaletra Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Lopinavir and Ritonavir AUC on Low Dose Tablet</title>
          <description>Lopinavir and Ritonavir AUC at 4 weeks when participants are receiving the study intervention, low dose tablet formulation of Kaletra. Data collection points for AUC were 0, 2, 4, 6, and 8 hours post dose.</description>
          <population>All participants were analyzed</population>
          <units>hr*ng/ml</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lpv AUC at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85670" spread="25184.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rtv AUC at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4876.1" spread="2541.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parent Satisfaction</title>
        <description>Parent Satisfaction Survey. Eight item Likert scale of parent/guardian satisfaction with the child's HIV treatment regimen. Item scores are summed to compute a total score. Total scores are reported with a minimum of 0 and a maximum of 32, with higher scores indicating higher satisfaction.</description>
        <time_frame>Baseline, 4 week, 12 weeks and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Kaletra Baseline</title>
            <description>Patients receiving Low Dose Kaletra at baseline</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Kaletra Week 4</title>
            <description>Patients Receiving Low Dose Kaletra at Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Parent Satisfaction</title>
          <description>Parent Satisfaction Survey. Eight item Likert scale of parent/guardian satisfaction with the child's HIV treatment regimen. Item scores are summed to compute a total score. Total scores are reported with a minimum of 0 and a maximum of 32, with higher scores indicating higher satisfaction.</description>
          <units>Score on a survey</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.75" spread="3.92"/>
                    <measurement group_id="O2" value="28.38" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=7</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 24 weeks after switch from liquid to low dose tablet formulation of Kaletra</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Kaletra</title>
          <description>Patients will serve as their own controls as they are switched from liquid Kaletra to Low Dose Tablet Kaletra
Low dose Kaletra tablets : Lopinavir/Ritonavir tablets 100mg/25mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased MCV</sub_title>
                <counts group_id="E1" events="23" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased Cholesterol</sub_title>
                <counts group_id="E1" events="24" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased Triglycerides</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>increased amylase</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased Monocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased WBC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decreased RBC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decreased plt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased eosinophils</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decreased neutrophil percent</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decreased ANC</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased lymphocyte percent</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>increased HCT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decreased CO2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>increased CO2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased Alk Phos</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Decreased Na+</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased K+</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decreased K+</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain due to previously scheduled orthopedic surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>leg pain</sub_title>
                <description>leg cramps or leg pain</description>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>leg fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>difficulty breathing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Laura Clarke-Steffen, PhD, RN</name_or_title>
      <organization>Phoenix Children's Hospital</organization>
      <phone>602-933-0234</phone>
      <email>lclarke@choenixchildrens.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

